Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nigella Sativa as Add-on to Atorvastatin in Hyperlipidemia
NCT06422650Phase 2Recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nigella sativa in hyperlipidemia (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Change in blood lipids at 8 weeks. Started Aug 2023; status: recruiting.
02
Drugs
nigella sativa
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06422650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422650.